A longitudinal Bayesian framework for estimating causal dose-response relationships
Yu Luo, Kuan Liu, Ramandeep Singh, Daniel J. Graham
TL;DR
The paper tackles estimating causal dose–response relationships for continuous, time-varying exposures in longitudinal data with time-varying confounding. It develops a scalable, nonparametric Bayesian framework that embeds a Dirichlet process prior into generalized estimating equations and uses a generalized Bayesian bootstrap to infer the marginal APO $\mu(d)$. Key contributions include identifiability of $\mu(d)$ under standard causal assumptions, DP-based GPS integration into GEE-based estimands, simulation validation showing valid uncertainty quantification and extrapolation beyond observed doses, and a real-world application linking mass transit ridership to COVID-19 transmission with policy implications. This approach provides probabilistic, flexible dose–response inference for longitudinal continuous exposures, enabling robust decision-making in transportation and public health contexts.
Abstract
Existing causal methods for time-varying exposure and time-varying confounding focus on estimating the average causal effect of a time-varying binary treatment on an end-of-study outcome, offering limited tools for characterizing marginal causal dose-response relationships under continuous exposures. We propose a scalable, nonparametric Bayesian framework for estimating marginal longitudinal causal dose-response functions with repeated outcome measurements. Our approach targets the average potential outcome at any fixed dose level and accommodates time-varying confounding through the generalized propensity score. The proposed approach embeds a Dirichlet process specification within a generalized estimating equations structure, capturing temporal correlation while making minimal assumptions about the functional form of the continuous exposure. We apply the proposed methods to monthly metro ridership and COVID-19 case data from major international cities, identifying causal relationships and the dose-response patterns between higher ridership and increased case counts.
